Firefly Bio

Johnson & Johnson’s $1 billion Firefly Bio acquisition adds the preclinical Firelink degrader antibody conjugate platform to its oncology pipeline, strengthening its research into KRAS-driven cancers and other difficult-to-treat solid tumors. Representative image.

Pharma & Biotech

Johnson & Johnson just spent $1bn on a preclinical cancer platform: What must Firefly Bio prove next?

by Pallavi Madhiraju
July 30, 2026
0 Comments

Johnson & Johnson closes its $1 billion Firefly Bio deal, adding a preclinical degrader antibody conjugate platform for KRAS-driven cancers.

Read More